About CV6
Therapeutics
CV6 Therapeutics is a clinical-stage biotechnology company based in Northern Ireland focused on amplifying the effectiveness of cornerstone therapies in oncology and inflammatory diseases relied on by millions of patients per year.
Through first-in-class medicines designed to work in combination with existing treatments, CV6 aims to deliver meaningful improvements in outcomes. Its lead program, CV6-168, is in Phase 1a trials, with additional programs advancing toward clinical development in autoimmune conditions.
Our Story: What is CV6?
Lorem ipsum dolor sit amet consectetur. In consectetur sollicitudin nibh elit iaculis mauris neque suspendisse. Congue suscipit elementum dolor eros. In sagittis volutpat arcu tortor magnis. Pulvinar tellus tellus varius quis leo proin orci sit. Tellus at sagittis sed mi purus tempus vestibulum eget. Congue mattis amet elit amet. Ac blandit sodales tortor purus nibh cras gravida. Convallis dictumst mauris duis vitae elit cras cras. Volutpat donec tincidunt risus fermentum aliquet.
Meet our team
Meet the experienced team behind CV6 Therapeutics, combining deep expertise in cancer biology, drug development, and clinical translation to advance innovative therapies that address resistance and improve patient outcomes.
Programs
View all
Oncology
CV6 is advancing therapies designed to improve outcomes in cancers where standard treatments remain essential but limited by resistance.
Inflamatory Diseases
CV6 is applying the same scientific approach to inflammatory diseases, including rheumatoid arthritis, where current treatments often fall short.